Is Ultragenyx Pharmaceutical (RARE) Below Fair Value Following Its $203 Million Voucher Sale?

Voucher sales inject fresh non dilutive cash

Ultragenyx Pharmaceutical (RARE) has agreed to sell a Rare Pediatric Disease Priority Review Voucher for US$203 million after FDA approval of Fayuvi for Sanfilippo syndrome type A, its second voucher deal within a week.

Ultragenyx Pharmaceutical’s stock has pulled back recently, with a 1-day share price return of 4.15% lower and a 7-day share price return of 6.07% lower, after a sharp 12.89% share price gain over 30 days and a much weaker 1-year total shareholder return of 55.45% lower, which hints that sentiment is still recovering despite the fresh non-dilutive cash from voucher sales.

Scan how Ultragenyx Pharmaceutical compares with other rare disease and high-research biotechs by reviewing our hand picked list of 20 high quality undiscovered gems in the sector.

Ultragenyx Pharmaceutical now has fresh voucher cash on the balance sheet, yet the share price still reflects years of heavy losses and a steep 1 year drawdown. Does that mix tilt the risk reward toward new buyers, or argue for patience?

Most Popular Narrative: 44.1% Undervalued

Against a last close of $14.54, the most followed narrative pegs Ultragenyx Pharmaceutical’s fair value at $26, which frames the voucher cash as only one small part of a much bigger turnaround story.

The "Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.

Here is why the market is mispricing the friction inside RARE’s operational engine.

See why 2 investors see Ultragenyx Pharmaceutical as 44% undervalued.

According to AnimalDoctorKwon, the tension sits in the gap between Ultragenyx Pharmaceutical’s science and its financial profile. Revenue of $717.0 million is set against a net loss of $586.0 million, and the narrative argues that this reflects a model where the costs of finding and serving rare disease patients soak up a large share of every incremental dollar.

The same thesis points to Crysvita and other partnered assets as less lucrative than headline product sales might suggest. Royalty deals and co promotion structures are described as diluting the economic value that reaches Ultragenyx Pharmaceutical’s shareholders, which feeds into the idea that even apparently strong top line progress may not translate cleanly into free cash flow.

Management quality and governance sit on the other side of the ledger. The firm’s leadership team has an average tenure of 9.5 years, and the board averages 10.5 years with 88% independent directors, which implies a high degree of experience and oversight. Emil Kakkis’ pay is above typical levels for similar sized businesses, yet is described as consistent with company performance over the past year, so the narrative tension is less about alignment and more about execution risk.

Forecast data feeding into the narrative adds further contrast. Earnings are expected to grow 76.52% per year with a path to profitability in the next 3 years, and revenue is projected to expand 18.1% annually compared with 13.5% for the broader US market. That profile supports a forecast return on equity of 27.4% in 3 years time, even though current liabilities exceed assets and shareholder equity is negative today.

The community view behind this fair value also leans on discounted cash flow work. Ultragenyx Pharmaceutical is described as trading 92.3% below an estimate of future cash flow value of $188.94, which is a very large gap. The narrative treats that spread as evidence that investors are heavily discounting the risk that losses continue and capital needs remain high before any forecast profitability arrives.

Shorter term share performance offers another clue to why the thesis is contentious. The stock has declined 55.45% on a total return basis over 1 year, 56.10% over 3 years, and 81.41% over 5 years, while also falling 38.39% year to date and 50.34% over 90 days. Those figures contrast sharply with the valuation models suggesting upside, and they feed into concerns that the market is still focused on cash burn and balance sheet strain.

At the same time, Ultragenyx Pharmaceutical screens as good value on several metrics used in the narrative. It trades at what is described as a good level compared to peers and the broader US Biotechs industry, and its current P/S ratio of 2x is framed as attractive versus both peer and industry averages in the supporting data, even though the narrative itself leans more on cash flow and profitability timing than on simple multiples.

The crux for readers is how to weigh these competing threads. On one side sits a seasoned management team, forecast profit growth, and a narrative fair value of $26 that is well above today’s $14.54 share price. On the other stand years of losses, negative equity, a short cash runway of less than 1 year, and user commentary that describes Ultragenyx Pharmaceutical as being on a “cash incinerating treadmill” unless restructuring and gene therapy launches change the economics.

Result: Fair Value of $26 (UNDERVALUED)

Still, Ultragenyx Pharmaceutical could see this underpriced story unwind quickly if restructuring fails to curb losses or if late stage candidates encounter regulatory setbacks.

Find out about the key risks to this Ultragenyx Pharmaceutical narrative.

Next Steps

If this mix of heavy losses, voucher cash, and valuation upside feels conflicted, do not wait for consensus to settle. Look deeper for yourself.

Take a few minutes to weigh the downside and upside drivers side by side, then pressure test your own thesis against the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical is only one piece of a much bigger opportunity set, and you do not want your watchlist anchored to a single turnaround story.

Use the Simply Wall St Screener to widen your opportunity set with ideas that match your risk appetite and return goals.

• Target potential upside by hunting for companies that combine quality fundamentals with attractive pricing using our hand picked 33 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with robust finances and room to withstand shocks through a curated list of solid balance sheet and fundamentals (25 results).
• Dial down volatility by zeroing in on steadier performers screened through a focused 32 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com